Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Clinical role
Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: The FDA material describes an aid to assessment rather than a primary diagnosis; applicability depends on the labeled adult glioma workflow and professional review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: The exact submission's labeled medical-image, measurement, or clinical-workflow inputs.
Who uses it?Intended users: Qualified healthcare professionals within the exact labeled clinical or procedural use.
What does the software produce?Output: Visualizations, segmentations, measurements, reconstructions, planning information, or other software outputs described in the exact FDA labeling.
What is its most important limitation?Key limitation: The FDA material describes an aid to assessment rather than a primary diagnosis; applicability depends on the labeled adult glioma workflow and professional review.
Clinical takeaway. Clinical role: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports comparative performance testing of the subject device against the predicate on a 100-patient subset (425 studies) of the MU-Glioma Post dataset, with both compared against expert manual segmentation ground truth established through a STAPLE-based consensus algorithm with final consensus approval by two board-certified neuroradiologists. Subject Device mean Dice similarity coefficient was 0.706 for the T1 enhancing region and 0.822 for the T2/FLAIR hyperintensity region. Software verification and validation was also reported. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
The FDA material describes an aid to assessment rather than a primary diagnosis; applicability depends on the labeled adult glioma workflow and professional review.
The exact FDA document reports comparative performance testing of the subject device against the predicate on a 100-patient subset (425 studies) of the MU-Glioma Post dataset, with both compared against expert manual segmentation ground truth established through a STAPLE-based consensus algorithm with final consensus approval by two board-certified neuroradiologists. Subject Device mean Dice similarity coefficient was 0.706 for the T1 enhancing region and 0.822 for the T2/FLAIR hyperintensity region. Software verification and validation was also reported. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Cercare conducted extensive performance validation testing and software verification and validation testing of the CMN Capillary Function with Oncology Virtual Expert." … "Comparative performance testing was performed for the Subject Device with respect to the Predicate Device using a 100-patient subset (425 studies) of the MU-Glioma Post dataset". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports comparative performance testing of the subject device against the predicate on a 100-patient subset (425 studies) of the MU-Glioma Post dataset, with both compared against expert manual segmentation ground truth established through a STAPLE-based consensus algorithm with final consensus approval by two board-certified neuroradiologists. Subject Device mean Dice similarity coefficient was 0.706 for the T1 enhancing region and 0.822 for the T2/FLAIR hyperintensity region. Software verification and validation was also reported. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Cercare conducted extensive performance validation testing and software verification and validation testing of the CMN Capillary Function with Oncology Virtual Expert." … "Comparative performance testing was performed for the Subject Device with respect to the Predicate Device using a 100-patient subset (425 studies) of the MU-Glioma Post dataset". Read from the exact FDA decision document on 2026-11-14.
No exact-product, version-specific sensitivity endpoint was established for this submission in the evidence set.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K260316 FDA evidence package for CMN Capillary Function with Oncology Virtual Expert
DesignFDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation.
PopulationPopulation and workflow are limited to the exact FDA labeling summarized for this submission.
Scopeexact submission
Tested versionExact FDA submission release; version not separately stated in the public decision material
IndependenceSponsor or vendor study
K260316
Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K260316 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: The exact submission's labeled medical-image, measurement, or clinical-workflow inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM and DICOM Structured Report inputs and outputs are described; installation on a standard PC or VMware virtual platform and remote desktop support are described.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: A standard PC or VMware virtual platform is described; exact hosting, service, and availability commitments are unknown.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Visualizations, segmentations, measurements, reconstructions, planning information, or other software outputs described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Visualizations, segmentations, measurements, reconstructions, planning information, or other software outputs described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM and DICOM Structured Report inputs and outputs are described; installation on a standard PC or VMware virtual platform and remote desktop support are described.
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
DICOM and DICOM Structured Report inputs and outputs are described; installation on a standard PC or VMware virtual platform and remote desktop support are described.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA material describes an aid to assessment rather than a primary diagnosis; applicability depends on the labeled adult glioma workflow and professional review.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04
Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-19Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, and GPi, and segment implanted leads for professional review.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.